PMID- 19515110
OWN - NLM
STAT- MEDLINE
DCOM- 20090915
LR  - 20131121
IS  - 1532-5415 (Electronic)
IS  - 0002-8614 (Linking)
VI  - 57
IP  - 8
DP  - 2009 Aug
TI  - A randomized, single-blind study of lansoprazole for the prevention of 
      exacerbations of chronic obstructive pulmonary disease in older patients.
PG  - 1453-7
LID - 10.1111/j.1532-5415.2009.02349.x [doi]
AB  - OBJECTIVES: To investigate whether proton pump inhibitor (PPI) therapy reduces 
      the frequency of common colds and exacerbations in patients with chronic 
      obstructive pulmonary disease (COPD). DESIGN: Twelve-month, randomized, 
      observer-blind, controlled trial. SETTING: A university hospital and three city 
      hospitals in Miyagi prefecture in Japan. PARTICIPANTS: One hundred patients with 
      COPD (mean age +/- SD 74.9 +/- 8.2) participated. They were all ex-smokers and 
      had received conventional therapies for COPD, including smoking cessation and 
      bronchodilators. Patients with gastroesophageal reflux disease or gastroduodenal 
      ulcer were excluded. INTERVENTION: Patients were randomly assigned to 
      conventional therapies (control group) or conventional therapies plus PPI 
      (lansoprazole 15 mg/d; PPI group) and observed for 12 months. MEASUREMENTS: 
      Frequency of common colds and COPD exacerbations. RESULTS: The number of 
      exacerbations per person in a year in the PPI group was significantly lower than 
      that in the control group (0.34 +/- 0.72 vs 1.18 +/- 1.40; P<.001). The adjusted 
      odds ratio with logistic regression for having exacerbation (> or =once/year) in 
      the PPI group compared with the control group was 0.23 (P=.004). In contrast, 
      there was no significant difference in the numbers of common colds per person per 
      year between the PPI group and the control group (1.22 +/- 2.09 vs 2.04 +/- 3.07; 
      P=.12). PPI therapy significantly reduced the risk of catching frequent common 
      colds (> or =3 times/year), the adjusted odds ratio of which was 0.28 (P=.048). 
      CONCLUSION: In this single-blind, nonplacebo-controlled trial, lansoprazole was 
      associated with a significant decrease in COPD exacerbations. More definitive 
      clinical trials are warranted.
FAU - Sasaki, Takahiko
AU  - Sasaki T
AD  - Department of Geriatric and Gerontology, School of Medicine, Tohoku University, 
      Sendai, Japan.
FAU - Nakayama, Katsutoshi
AU  - Nakayama K
FAU - Yasuda, Hiroyasu
AU  - Yasuda H
FAU - Yoshida, Motoki
AU  - Yoshida M
FAU - Asamura, Takaaki
AU  - Asamura T
FAU - Ohrui, Takashi
AU  - Ohrui T
FAU - Arai, Hiroyuki
AU  - Arai H
FAU - Araya, Jun
AU  - Araya J
FAU - Kuwano, Kazuyoshi
AU  - Kuwano K
FAU - Yamaya, Mutsuo
AU  - Yamaya M
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PT  - Research Support, Non-U.S. Gov't
DEP - 20090608
PL  - United States
TA  - J Am Geriatr Soc
JT  - Journal of the American Geriatrics Society
JID - 7503062
RN  - 0 (2-Pyridinylmethylsulfinylbenzimidazoles)
RN  - 0 (Anti-Infective Agents)
RN  - 0K5C5T2QPG (Lansoprazole)
SB  - IM
MH  - 2-Pyridinylmethylsulfinylbenzimidazoles/*therapeutic use
MH  - Aged
MH  - Anti-Infective Agents/*therapeutic use
MH  - Common Cold/*drug therapy
MH  - Female
MH  - Humans
MH  - Japan
MH  - Lansoprazole
MH  - Logistic Models
MH  - Male
MH  - Pulmonary Disease, Chronic Obstructive/*drug therapy/*physiopathology
MH  - Single-Blind Method
MH  - Treatment Outcome
EDAT- 2009/06/12 09:00
MHDA- 2009/09/16 06:00
CRDT- 2009/06/12 09:00
PHST- 2009/06/12 09:00 [entrez]
PHST- 2009/06/12 09:00 [pubmed]
PHST- 2009/09/16 06:00 [medline]
AID - JGS2349 [pii]
AID - 10.1111/j.1532-5415.2009.02349.x [doi]
PST - ppublish
SO  - J Am Geriatr Soc. 2009 Aug;57(8):1453-7. doi: 10.1111/j.1532-5415.2009.02349.x. 
      Epub 2009 Jun 8.